Trial reportEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2026
A prospective, double-blind, randomised controlled trial comparing oral versus intravenous tranexamic acid for blood loss reduction in primary total knee arthroplasty.
Trial report in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTotal knee arthroplasty (TKA) is associated with significant perioperative blood loss. While intravenous tranexamic acid (TXA) effectively reduces bleeding, oral TXA may offer comparable efficacy with economic and logistical advantages. We assessed whether oral TXA is non-inferior to intravenous TXA for reducing blood loss following primary total knee arthroplasty.
methodsThis prospective, double-blind, randomised controlled trial included 60 patients undergoing primary cemented TKA between September 2019 and March 2020. Patients were randomised (1:1) to receive either 2 g oral TXA administered 2 h preoperatively or 1 g intravenous TXA at induction of anaesthesia. Both groups received matched placebos to maintain blinding. The primary outcome was reduction in haemoglobin concentration from baseline to postoperative day 5. Secondary outcomes included calculated total blood loss, drain output, transfusion rate, length of hospital stay, and adverse events. Statistical analysis followed intention-to-treat principles.
resultsMean haemoglobin reduction was 2.60 ± 0.95 g/dL in the oral TXA group versus 2.71 ± 1.18 g/dL in the intravenous group (mean difference = - 0.11 g/dL; 95% CI: - 0.64 to 0.42; p = 0.68). Calculated total blood loss was 802.8 ± 286.4 mL versus 848.9 ± 421.5 mL respectively (p = 0.62). Drain output on postoperative day 1 was higher with oral TXA (256.7 ± 129.1 vs 192.5 ± 89.9 mL; p = 0.03) but similar on day 2 (130.1 ± 61.9 vs 119.3 ± 50.8 mL; p = 0.46). Transfusion rates were 10.0% (3/30) versus 3.3% (1/30) (p = 0.31). No thromboembolic events occurred in either group.
conclusionsOral TXA administered preoperatively demonstrates non-inferiority to intravenous TXA for reducing perioperative blood loss in primary TKA. Despite a clinically relevant but statistically non-significant trend toward higher transfusion rates with oral TXA in this small sample, oral administration represents a safe and substantially more cost-effective alternative (80% cost savings), particularly suitable for resource-constrained healthcare environments and ambulatory surgery settings.
Indexed as
Identifiers
41528556What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.